•  
  •  
 

Subject Area

Obstetrics and Gynecology

Article Type

Original Study

Abstract

Objectives The aims of this study were to assess whether metabolic syndrome (MetS) is more common in chronic obstructive pulmonary disease (COPD) patients and to elucidate the role of C-reactive protein (CRP) as a marker of MetS in COPD patients. Background MetS is closely related to COPD as proved in many previous studies. This association is attributed to the presence of systemic inflammation in both conditions. CRP may play a role as a predictor of MetS in COPD patients. Patients and methods This case–control study included 30 COPD patients and 20 controls recruited from the Chest Department, Faculty of Medicine, Menoufia University and Shebin El-Kom Chest Hospital between August 2014 and August 2016. All participants underwent clinical, spirometric, and laboratory assessments. Patients were staged according to Global initiative for Obstructive Lung Disease classification, and MetS was diagnosed according to International Diabetes Federation criteria. Results Patients had significantly higher systolic and diastolic blood pressures, cholesterol, low-density lipoprotein, fasting blood glucose, CRP, and serum uric acid compared with controls (P < 0.001, 0.002, <0.001, 0.007, <0.001, <0.001, and < 0.001, respectively). High-density lipoprotein was significantly lower in controls. MetS in patients (60%) was more common compared with controls (30%) (P = 0.03). CRP levels were higher in COPD patients with MetS compared with COPD patients without MetS (P < 0.001). CRP more than 14 mg/l predicts the presence of MetS in COPD patients with specificity of 83.33% and sensitivity of 88.89%. Conclusion MetS is a common comorbidity associated with COPD. CRP can be a useful predictor of MetS in COPD patients.

Download

Share

COinS